Kvalita života pacientů po transanální totální mezorektální excizi - naše zkušenosti

Title in English Quality of life after transanal total mesorectal excision – our experience


Year of publication 2021
Type Article in Periodical
Magazine / Source Rozhledy v chirurgii
MU Faculty or unit

Faculty of Medicine

Web https://www.prolekare.cz/casopisy/rozhledy-v-chirurgii/2021-11-1/kvalita-zivota-pacientu-po-transanalni-totalni-mezorektalni-excizi-nase-zkusenosti-129335
Doi http://dx.doi.org/10.33699/PIS.2021.100.11.534-542
Keywords transanal total mesorectal excision; quality of life; functional outcomes; low anterior resection syndrome; EORTC
Description Introduction: Functional outcomes and quality of life (QoL) after transanal total mesorectal excision (TaTME) are very important factors in the evaluation of TaTME in comparison with other approaches to TME. The most common functional problems after resection of the rectum include bowel, urologic and sexual dysfunctions. In this study, we present our experience with QoL after TaTME; the results are compared with worldwide literature in the discussion. Methods: QoL was assessed by a questionnaire. The total of 54 patients were analysed. A general questionnaire for oncological diseases was used – European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30, together with EORTC-QLQ-CR29 – a specific questionnaire for colorectal cancer. The Low Anterior Resection Syndrome (LARS) score was also obtained in all patients. Mean follow-up was 42.65 months (range 9–91 months). Results: The mean LARS score in patients undergoing TaTME was 30.7 while a major LARS was observed in 64.2% of those with LARS. Of all of the symptoms in the EORTC-QLQ-C30 survey, the most serious problems which affected patients undergoing TaTME were diarrhoea (30.25), fatigue (23.87) and insomnia (20.37). In the QLQ-CR29 survey the problems included flatulence (50.94), faecal incontinence (45.06) and stool frequency (35.19). The results of EORTC-QLQ-C30 and QLQ-CR29 are quite heterogeneous. Conclusion: In this study the QoL of patients with advanced rectal tumours (of whom 81.5% received neoadjuvant therapy) undergoing TaTME is comparable to results in the current literature. The most severe symptoms affecting QoL after TaTME are flatulence, faecal incontinence, and stool frequency. Other serious symptoms include fatigue and insomnia. LARS was recorded in 73.6% of patients undergoing TaTME, mostly a major LARS.

You are running an old browser version. We recommend updating your browser to its latest version.

More info